Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 48Rectal Neoplasms 29Stomach Neoplasms 24Colorectal Neoplasms 24Triple Negative Breast Neoplasms 18Neoplasm Metastasis 10Nasopharyngeal Carcinoma 10Colonic Neoplasms 10Locally Advanced Rectal Cancer 7Esophageal Neoplasms 7Biliary Tract Neoplasms 7Brain Neoplasms 5Adenocarcinoma Of Esophagus 5Adenocarcinoma 5Pancreatic Neoplasms 4Neoplasms 4Gastrointestinal Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Neuroendocrine Tumors 3HER2-positive Breast Cancer 3Cholangiocarcinoma 3Advanced Solid Tumors 3Recurrence 2Neoplasm, Residual 2Meningeal Neoplasms 2Locally Advanced Colorectal Cancer 2Esophageal Squamous Cell Carcinoma 2Early Low Rectal Cancer 2Colorectal Cancer Metastatic 2

Interventions

penpulimab 1lutetium Lu 177 dotatate 1copper dotatate CU-64 1XELOX 1Oxaliplatin 1Lutetium-177 1Lutetium 1IDRX-42 1Drug Therapy 1Colonoscopy 1Capecitabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Digestive System Diseases × Capecitabine × Clear all
NCT05494060 2023-11-07

EXPLORING

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Recruiting
80 enrolled
Gastrointestinal

Carcinoma, Digestive System Diseases, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡